152 related articles for article (PubMed ID: 20173087)
1. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
Zeamari S; Floot B; van der Vange N; Stewart FA
Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
[TBL] [Abstract][Full Text] [Related]
3. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
7. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity.
Kusamura S; Baratti D; Younan R; Laterza B; Oliva GD; Costanzo P; Favaro M; Gavazzi C; Grosso F; Deraco M
Ann Surg Oncol; 2007 Sep; 14(9):2550-8. PubMed ID: 17558537
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
10. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
11. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
van Ruth S; Mathôt RA; Sparidans RW; Beijnen JH; Verwaal VJ; Zoetmulder FA
Clin Pharmacokinet; 2004; 43(2):131-43. PubMed ID: 14748621
[TBL] [Abstract][Full Text] [Related]
14. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
[TBL] [Abstract][Full Text] [Related]
16. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Bartlett DL; Buell JF; Libutti SK; Reed E; Lee KB; Figg WD; Venzon DJ; Alexander HR
Cancer; 1998 Sep; 83(6):1251-61. PubMed ID: 9740093
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.
Kusamura S; Younan R; Baratti D; Costanzo P; Favaro M; Gavazzi C; Deraco M
Cancer; 2006 Mar; 106(5):1144-53. PubMed ID: 16456817
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
20. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.
Gilly FN; Beaujard A; Glehen O; Grandclement E; Caillot JL; Francois Y; Sadeghi-Looyeh B; Gueugniaud PY; Garbit F; Benoit M; Bienvenu J; Vignal J
Anticancer Res; 1999; 19(3B):2317-21. PubMed ID: 10472351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
